Compare ASUR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | IFRX |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.5M | 225.5M |
| IPO Year | 1996 | 2017 |
| Metric | ASUR | IFRX |
|---|---|---|
| Price | $9.77 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $13.33 | $8.36 |
| AVG Volume (30 Days) | 218.5K | ★ 983.2K |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,952,000.00 | N/A |
| Revenue This Year | $15.89 | N/A |
| Revenue Next Year | $13.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 63.39 | N/A |
| 52 Week Low | $6.80 | $0.80 |
| 52 Week High | $10.20 | $2.95 |
| Indicator | ASUR | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 76.93 | 46.69 |
| Support Level | $7.97 | $1.58 |
| Resistance Level | $10.01 | $2.44 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.33 | 0.04 |
| Stochastic Oscillator | 91.91 | 66.34 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.